Literature DB >> 20829623

Pathophysiology of diabetes mellitus in Cushing's syndrome.

Rosario Pivonello1, Monica De Leo, Pasquale Vitale, Alessia Cozzolino, Chiara Simeoli, Maria Cristina De Martino, Gaetano Lombardi, Annamaria Colao.   

Abstract

Cushing's syndrome is commonly complicated with an impairment of glucose metabolism, which is often clinically manifested as diabetes mellitus. The development of diabetes mellitus in Cushing's syndrome is both a direct and indirect consequence of glucocorticoid excess. Indeed, glucocorticoid excess induces a stimulation of gluconeogenesis in the liver as well as an inhibition of insulin sensitivity both in the liver and in the skeletal muscles, which represent the most important sites responsible for glucose metabolism. In particular, glucocorticoid excess stimulates the expression of several key enzymes involved in the process of gluconeogenesis, with a consequent increase of glucose production, and induces an impairment of insulin sensitivity either directly by interfering with the insulin receptor signaling pathway or indirectly, through the stimulation of lipolysis and proteolysis and the consequent increase of fatty acids and amino acids, which contribute to the development of insulin resistance. Moreover, the peculiar distribution of adipose tissue throughout the body, with the predominance of visceral adipose tissue, significantly contributes to the worsening of insulin resistance and the development of a metabolic syndrome, which participates in the occurrence and maintenance of the impairment of glucose tolerance. Finally, glucocorticoid excess is able to impair insulin secretion as well as act at the level of the pancreatic beta cells, where it inhibits different steps of the insulin secretion process. This phenomenon is probably responsible for the passage from an impairment of glucose tolerance to an overt diabetes mellitus in susceptible patients with Cushing's syndrome.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20829623     DOI: 10.1159/000314319

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  54 in total

Review 1.  Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.

Authors:  M G Baroni; F Giorgino; V Pezzino; C Scaroni; A Avogaro
Journal:  J Endocrinol Invest       Date:  2015-12-30       Impact factor: 4.256

2.  Low-dose dexamethasone administration for 3 weeks favorably affects plasma HDL concentration and composition but does not affect very low-density lipoprotein kinetics.

Authors:  Xuewen Wang; Faidon Magkos; Bruce W Patterson; Dominic N Reeds; Janine Kampelman; Bettina Mittendorfer
Journal:  Eur J Endocrinol       Date:  2012-05-22       Impact factor: 6.664

Review 3.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

4.  Transcriptional regulation of FoxO3 gene by glucocorticoids in murine myotubes.

Authors:  Taiyi Kuo; Patty H Liu; Tzu-Chieh Chen; Rebecca A Lee; Jenny New; Danyun Zhang; Cassandra Lei; Andy Chau; Yicheng Tang; Edna Cheung; Jen-Chywan Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-01-12       Impact factor: 4.310

5.  Angiopoietin-like 4 (Angptl4) protein is a physiological mediator of intracellular lipolysis in murine adipocytes.

Authors:  Nora E Gray; Lily N Lam; Karen Yang; Anna Y Zhou; Suneil Koliwad; Jen-Chywan Wang
Journal:  J Biol Chem       Date:  2012-01-19       Impact factor: 5.157

6.  Altered miRNA processing disrupts brown/white adipocyte determination and associates with lipodystrophy.

Authors:  Marcelo A Mori; Thomas Thomou; Jeremie Boucher; Kevin Y Lee; Susanna Lallukka; Jason K Kim; Martin Torriani; Hannele Yki-Järvinen; Steven K Grinspoon; Aaron M Cypess; C Ronald Kahn
Journal:  J Clin Invest       Date:  2014-07-01       Impact factor: 14.808

Review 7.  Glucose metabolism in Cushing's syndrome.

Authors:  Anu Sharma; Adrian Vella
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2020-06       Impact factor: 3.243

Review 8.  Glucose metabolism in patients with subclinical Cushing's syndrome.

Authors:  Roberta Giordano; Federica Guaraldi; Rita Berardelli; Ioannis Karamouzis; Valentina D'Angelo; Elisa Marinazzo; Andreea Picu; Ezio Ghigo; Emanuela Arvat
Journal:  Endocrine       Date:  2012-03-06       Impact factor: 3.633

Review 9.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 10.  Metabolic functions of glucocorticoid receptor in skeletal muscle.

Authors:  Taiyi Kuo; Charles A Harris; Jen-Chywan Wang
Journal:  Mol Cell Endocrinol       Date:  2013-03-21       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.